Ignite Creation Date:
2024-05-06 @ 3:56 PM
Last Modification Date:
2024-10-26 @ 1:59 PM
Study NCT ID:
NCT04803721
Status:
RECRUITING
Last Update Posted:
2024-03-29
First Post:
2021-03-11
Brief Title:
Interplay Between Immune and Metabolic Programs in Myelodysplastic Syndromes
Sponsor:
University Hospital Toulouse
Organization:
University Hospital Toulouse
Study Overview
Official Title:
Interplay Between Immune and Metabolic Programs in Myelodysplastic Syndromes Involvement in Leukemia Transformation and Therapeutic Targeting
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IMET-MDS
Brief Summary:
Myelodysplastic syndromes MDS are a pre-leukemic condition with an extremely poor prognosis despite current treatments that justify new therapeutic approaches Various studies have described the potential involvement of both immune compartment and cellular metabolism in the pathophysiology of MDS The aim of this study is to determine the specific immune and metabolic profiles of the different classes of MDS and to identify predictive markers of progressionsurvivalresponse to therapy
Detailed Description:
Myelodysplastic syndromes MDS are a pre-leukemic condition with an extremely poor prognosis despite current treatments It is the most frequent haematological disorder after the age of 65 Different approaches targeting the immune compartment have been developed but preliminary results seem to show variable response rates to these therapeutic highlighting the heterogeneity of MDS and the need to identify detailed immune profiles that are predictive of disease progression and can help in treatment choices It therefore seems essential to complement the knowledge of immune profiles with an understanding of the metabolic profiles of MDS patients as well as the links between these profiles and changes associated with progression andor treatment resistance in order to consider new therapeutic pathways
Fresh samples from patients with MDS will be used to perform flow cytometry mapping of immune populations T-cell and blast cell metabolism Subsequently a study of energy metabolism will be conducted using an extracellular flow analyzer and a sensitivity test for certain molecules targeting metabolic pathways If possible samples will be taken at different times during the course of treatment according to the therapeutic protocols diagnosis progressiontransformation during azacitidine treatment
Fresh samples from patients with MDS will be used to perform flow cytometry mapping of immune populations T-cell and blast cell metabolism Subsequently a study of energy metabolism will be conducted using an extracellular flow analyzer and a sensitivity test for certain molecules targeting metabolic pathways If possible samples will be taken at different times during the course of treatment according to the therapeutic protocols diagnosis progressiontransformation during azacitidine treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None